SEA-BCMA is a new antibody targeting the BCMA protein and being tested in multiple myeloma. It was made using proprietary Sugar Engineered Antibody (SEA) technology, which adds sugar molecules to the original antibody. The approach is believed to improve the binding of anti-tumor immune cells to the antibody, enhancing the immune response against cancer.
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
There are no resources, links or videos to display for this treatment.